Company profile
Celularity Inc.
NASDAQ: CELU · Healthcare · Biotechnology
#518 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
31DFH 35DQ 16GM 42SS 50
v0.1 · 65/100 weight · provisional
↑ workforce scale, 3-yr revenue growth · ↓ filing timeliness, revenue growth (YoY)
Methodology →Revenue TTM
$26.6M
Rev growth YoY (TTM)
-51.0%
Net income (FY)
-$91.7M
Employees
115
as of 2026-08-22
Market cap
$23.2M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$26.6M$26.6M2025
Net income-$91.7M-$91.7M2025
Operating income-$61.3M-$61.3M2025
Total assets$107.3M$107.3M2025
Liabilities$145.4M$145.4M2025
Equity-$38.1M-$38.1M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product50%
License Royalty and Other30%
Service20%
By geography
Not disclosed.
The read
What is Celularity Inc.’s revenue?
Celularity Inc. booked $26.6M in FY2025 revenue, contracting 51% year over year — slower than 82% of Healthcare companies we track, at a -345.4% net margin.
Peers · Healthcare
Sensus Healthcare, Inc.51DCue Biopharma, Inc.49DINNOCAN PHARMA Corp59CNeurobiological Technologies, Inc.——Synovics Pharmaceuticals, Inc.——Biocept, Inc.——Neighbors
Morris →Key facts
CEORobert Joseph Hariri
SectorHealthcare
IndustryBiotechnology
HeadquartersFlorham Park, NJ
ExchangeNASDAQ: CELU
Employees115
IPO date2019-08-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.